natgillin/translations-raw huggingface dataset:
This will yield a reconstituted stock solution containing 20 mg/ml or 10 mg/ml etoposide. 
Tako dobimo rekonstituirano osnovno raztopino, ki vsebuje 20 mg/ml ali 10 mg/ml etopozida.
Ovarian cancer; small cell lung cancer; gestational trophoblastic neoplasia; testicular cancer 
Rak jajčnikov; drobnocelični pljučni rak; gestacijska trofoblastna neoplazija; rak mod
Etoposide (as phosphate) 
etopozid (v obliki fosfata)
ETOPOPHOS and associated names is for single use only. 
Zdravilo ETOPOPHOS in povezana imena je namenjeno samo za enkratno uporabo.
Transient hypotension following rapid intravenous administration has been reported in patients treated with etoposide phosphate and has not been associated with cardiac toxicity or electrocardiographic changes. 
Po hitrem intravenskem dajanju etopozid fosfata so poročali o prehodni hipotenziji, ki ni bila povezana s kardiotoksičnostjo ali elektrokardiografskimi spremembami.
Granulocyte and platelet nadirs tend to occur about 10 to14 days after administration of etoposide phosphate depending on the way of administration and treatment scheme. 
Najnižje vrednosti granulocitov in trombocitov se navadno pojavijo približno 10 do 14 dni po prejetju etopozid fosfata in so odvisne od načina dajanja in sheme zdravljenja.
The stopper of the vial should be pierced only once and a sterile transfusion set or any other auxiliary device should be used for withdrawal for the solution. 
Zamašek viale se sme predreti le enkrat, za odvzem raztopine a je treba uporabiti sterilen set za transfuzijo ali drug pripomoček.
What you need to know before you are given ETOPOPHOS and associated names 
Kaj morate vedeti, preden boste prejeli zdravilo ETOPOPHOS in povezana imena
To be completed nationally 
Izpolni država članica.
The doses after the initial dose should be adjusted if neutrophil count is below 500 cells/mm3 for more than 5 days. 
Odmerke, ki sledijo začetnemu odmerku, je treba prilagoditi, če je število nevtrofilcev pod 500/mm3 več kot 5 dni.
[See Annex 1 - To be completed nationally] 
[Glejte Prilogo I - izpolni država članica.]
Anaphylactic reactions can occur with the initial dose of etoposide phosphate. 
Reakcije anafilaktičnega tipa se lahko pojavijo med začetnim odmerkom etopozid fosfata.
The following haematological parameters should be measured at the start of therapy and prior to each subsequent dose of ETOPOPHOS and associated names: platelet count, haemoglobin, white blood cell count and differential. 
Pred začetkom zdravljenja in pred vsakim naslednjim odmerkom zdravila ETOPOPHOS in povezana imena je treba izmeriti naslednje hematološke parametre: število trombocitov, hemoglobin, število levkocitov in diferencialno krvno sliko.
If you are given more ETOPOPHOS and associated names than you should 
Če prejmete več zdravila ETOPOPHOS in povezana imena, kot bi smeli
Tumour lysis syndrome (sometimes fatal) has been reported following the use of etoposide phosphate in association with other chemotherapeutic drugs (see section 4.4). 
O sindromu tumorske lize (ki je bil včasih smrten) so poročali po uporabi etopozid fosfata skupaj z drugimi kemoterapevtiki (glejte poglavje 4.4).
Vascular disorders common hypertension, transient systolic hypotension following rapid intravenous administration uncommon haemorrhage 
Žilne bolezni pogosti hipertenzija, prehodna sistolična hipotenzija po hitri intravenski uporabi občasni krvavitev
In patients with creatinine clearance less than 15 mL/min and on dialysis further dose reduction should be considered. 
Pri bolnikih z očistkom kreatinina pod 15 ml/min, ki prejemajo dializo, je treba razmisliti o nadaljnjem zmanjšanju odmerka.
Dosage should be modified to take into account the myelosuppressive effects of other drugs in the combination or the effects of prior radiotherapy or chemotherapy (see section 4.4) which may have compromised bone marrow reserve. 
Odmerjanje zdravila je treba prilagoditi glede na možne mielosupresivne učinke drugih zdravil, ki se uporabljajo v kombiniranem zdravljenju, ali glede na učinke predhodne radioterapije ali kemoterapije (glejte poglavje 4.4), ki so morda zmanjšali zalogo kostnega mozga.
ETOPOPHOS and associated names should only be administered and monitored under the supervision of a qualified physician experienced in the use of anti-neoplastic medicinal products (see section 4.4). 
Zdravljenje z zdravilom ETOPOPHOS in povezana imena lahko uvede in nadzira le usposobljen zdravnik, ki ima izkušnje z uporabo zdravil za zdravljenje novotvorb (glejte poglavje 4.4).
Doses subsequent to initial dose should be adjusted if neutrophil count less than 500 cells/mm3 occurs for more than 5 days or is associated with fever or infection, if platelet count less than 25,000 cells/mm3 occurs, if any grade 3 or 4 toxicity develops or if renal clearance is less than 50 ml/min. 
Odmerke, ki sledijo začetnemu odmerku, je treba prilagoditi, če je število nevtrofilcev pod 500 celic/mm3 več kot 5 dni ali se pojavita tudi zvišana telesna temperatura ali okužba, če je število trombocitov pod 25.000 celic/mm3, če se pojavi kateri od neželenih učinkov 3. ali 4. stopnje toksičnosti ali če je ledvični očistek nižji od 50 ml/min.
Etoposide phosphate is metabolised in vivo into the active substance etoposide by a process of dephosphorylation. 
Etopozid fosfat se in vivo presnavlja v učinkovino etopozid s postopkom defosforilacije.
No dosage adjustment is necessary in elderly patients (age > 65 years old), other than based on renal function. 
Pri starejših bolnikih (starost > 65 let) prilagajanje odmerka ni potrebno, razen zmanjšanja na osnovi delovanja ledvic.
When restarting the infusion, a slower administration rate should be used. 
Ob ponovnem začetku dajanja infuzije mora biti infundiranje počasnejše.
How to store ETOPOPHOS and associated names Contents of the pack and other information 
Shranjevanje zdravila ETOPOPHOS in povezana imena Vsebina pakiranja in dodatne informacije
Gestational trophoblastic neoplasia 
Gestacijska trofoblastna neoplazija
Hepatobiliary disorders very common alanine aminotransferase increased, alkaline phosphatase increased, aspartate amino transferase increased, bilirubin increased, hepatotoxicity 
Bolezni jeter, žolčnika in žolčevodov zelo pogosti zvečana vrednost alaninaminotransferaze, zvečana vrednost alkalne fosfataze, zvečana vrednost aspartat-aminotransferaze, zvečana vrednost bilirubina, hepatotoksičnost
If ETOPOPHOS and associated names solution contacts the skin or mucosa, immediately wash the skin with soap and water and flush the mucosa with water (see section 6.6). 
Če pride raztopina zdravila ETOPOPHOS in povezana imena v stik s kožo ali sluznico, je treba kožo takoj umiti z milom in vodo, sluznico pa izprati z vodo (glejte poglavje 6.6).
Gastrointestinal disorders very common abdominal pain, anorexia, constipation, nausea and vomiting common diarrhoea, mucositis (including stomatitis and esophagitis) 
Bolezni prebavil zelo pogosti abdominalna bolečina, anoreksija, zaprtje, navzea in bruhanje pogosti diareja, mukozitis (vključno s stomatitisom in ezofagitisom)
- cancer of the blood (acute myeloid leukaemia) - tumour in the lymphatic system (Hodgkin's lymphoma, non-Hodgkin's lymphoma) 
- krvni rak (akutna mieloblastna levkemija) - tumor v limfnem sistemu (Hodgkinov limfom, ne-Hodgkinov limfom)
Injection site reaction 
Reakcija na mestu injiciranja
Skin reactions associated with accidental exposure to ETOPOPHOS and associated names may occur. 
Pojavijo se lahko kožne reakcije, povezane z naključno izpostavljenostjo zdravilu ETOPOPHOS in povezana imena.
These reactions have usually responded promptly to the cessation of the infusion and administration of pressor agents, corticosteroids, antihistamines, or volume expanders as appropriate. 
Ti neželeni učinki so se običajno takoj odzvali na prekinitev infundiranja in na dajanje zdravil za zvišanje krvnega tlaka, kortikosteroidov, antihistaminikov ali plazemskih ekspanderjev.
Physicians should be aware of the possible occurrence of an anaphylactic reaction with ETOPOPHOS and associated names, manifested by chills, pyrexia, tachycardia, bronchospasm, dyspnoea and hypotension, which can be fatal. 
Zdravnik mora biti pozoren na možnost anafilaktične reakcije pri zdravljenju z zdravilom ETOPOPHOS in povezana imena, ki se kaže kot mrzlica, zvišana telesna temperatura, tahikardija, bronhospazem, dispneja in hipotenzija, in se lahko konča s smrtjo.
- testicular cancer - small cell lung cancer - cancer of the blood (acute myeloid leukaemia) - tumour in the lymphatic system (Hodgkin's lymphoma, non-Hodgkin's lymphoma) - reproductive system cancers (gestational trophoblastic neoplasia and ovarian cancer) 
- krvni rak (akutna mieloična levkemija) - tumor v limfnem sistemu (Hodgkinov limfom, ne-Hodgkinov limfom) - raki reproduktivnega sistema (gestacijska trofoblastna neoplazija in rak jajčnikov)
Dose limiting bone marrow suppression is the most significant toxicity associated with ETOPOPHOS and associated names therapy. 
Mielosupresija, ki omejuje nadaljnje odmerjanje, je najpomembnejši toksični učinek zdravila ETOPOPHOS in povezana imena.
Subsequent dosing should be based on patient tolerance and clinical effect. 
Naslednji odmerki so odvisni od bolnikovega prenašanja etopozida in kliničnega učinka.
Leucopenia and severe leucopenia (less than 1,000 cells/mm3) were observed in 91% and 17%, respectively, for etoposide phosphate. 
Levkopenijo so opazili pri 91 %, hudo levkopenijo (manj kot 1.000 celic/mm3) pa pri 17 % bolnikov, zdravljenih z etopozid fosfatom.
Only use clear solutions. 
Uporabite le bistre raztopine.
QUALITATIVE AND QUANTITATIVE COMPOSITION Each vial contains 113.6 mg etoposide phosphate equivalent to 100 mg etoposide. 
KAKOVOSTNA IN KOLIČINSKA SESTAVA Ena viala vsebuje 100 mg etopozida v obliki 113,6 mg etopozid fosfata.
No delayed hypotension has been noted. 
Hipotenzije, ki bi se pojavila naknadno, niso opazili.
Dosage should be modified to take into account the myelosuppressive effects of other drugs in the combination or the effects of prior radiation therapy or chemotherapy which may have compromised bone marrow reserve. 
Odmerjanje zdravila je treba prilagoditi glede na možne mielosupresivne učinke drugih zdravil, ki se uporabljajo v kombiniranem zdravljenju, ali glede na učinke predhodne radioterapije ali kemoterapije, ki so morda zmanjšali zalogo kostnega mozga.
General disorders and administration site conditions very common asthenia, malaise common extravasation****, phlebitis rare pyrexia 
Splošne težave in spremembe na mestu aplikacije zelo pogosti astenija, splošno slabo počutje pogosti ekstravazacija****, flebitis redki pireksija
ETOPOPHOS and associated names is a white to off-white dry powder. 
Zdravilo ETOPOPHOS in povezana imena je bel do umazano bel prašek.
This will yield a reconstituted stock solution containing 10 mg/ml etoposide. 
Tako dobimo rekonstituirano osnovno raztopino, ki vsebuje 10 mg/ml etopozida.
ETOPOPHOS and associated names is used in the treatment of certain types of cancers in children: 
Zdravilo ETOPOPHOS in povezana imena uporabljamo za zdravljenje določenih vrst raka pri otrocih:
Other medicines and ETOPOPHOS and associated names 
Druga zdravila in zdravilo ETOPOPHOS in povezana imena
Preparation of Intravenous Solution 
POSTOPEK UPORABE intravenska uporaba
Follow up doses should be adjusted in case of occurrence of grade 3 or 4 toxicities or if renal creatinine clearance is below 50 ml/min. 
Odmerke, ki sledijo začetnemu odmerku, je treba prilagoditi, če se pojavijo neželeni učinki 3. ali 4. stopnje toksičnosti ali če je ledvični očistek nižji od 50 ml/min.
*Myelosuppression with fatal outcome has been reported **Anaphylactic reactions can be fatal ***Seizure is occasionally associated with allergic reactions. 
***Konvulzije so občasno povezane z alergijskimi reakcijami.
ETOPOPHOS and associated names is indicated for the treatment of platinum-resistant/refractory epithelial ovarian cancer in adults. 
Zdravilo ETOPOPHOS in povezana imena je indicirano za zdravljenje na platino odpornega/refraktarnega epitelijskega raka jajčnikov pri odraslih.
- The active substance is etoposide phophate. 
- Učinkovina je etopozid fosfat.
Do not take ETOPOPHOS and associated names 
Ne jemljite zdravila ETOPOPHOS in povezana imena
The products administered by parenteral route must be visually examined to check for any particulates or discoloration prior to administration. 
Zdravila za parenteralno dajanje je treba pred dajanjem vizualno pregledati glede prisotnosti delcev ali obarvanosti.
ETOPOPHOS and associated names should only be administered and monitored under the supervision of a qualified physician experienced in the use of anti-neoplastic medicinal products. 
Zdravljenje z zdravilom ETOPOPHOS in povezana imena lahko uvede in nadzira le usposobljen zdravnik, ki ima izkušnje z uporabo zdravil za zdravljenje novotvorb.
Severe liver, kidney or heart damage from a condition called tumour lysis syndrome, caused by harmful amounts of substances from the cancer cells getting into the blood stream, has been seen sometimes when ETOPOPHOS and associated names is taken along with other drugs used to treat cancer. 
Ob jemanju zdravila ETOPOPHOS skupaj z drugimi zdravili za zdravljenje raka so včasih opazili hudo okvaro jeter, ledvic ali srca, ki nastopi zaradi zapleta, imenovanega sindrom tumorske lize, ki ga povzroči sproščanje škodljivih količin snovi iz rakavih celic v krvni obtok.
Preparation of ETOPOPHOS and associated names 1000 mg powder for solution for infusion 
Priprava zdravila ETOPOPHOS in povezana imena 1000 mg prašek za raztopino za infundiranje
Two dose-dependent responses are seen: At high concentrations (10 mcg/mL or more), cells entering mitosis are lysed; at low concentrations (0.3 to 10 mcg/mL), cells are inhibited from entering prophase. 
Kaže Kaže dvojno od odmerka odvisno delovanje: pri višjih koncentracijah (10 μg/ml ali več) pride do lize celic, ki vstopajo v mitozo.
• difficulty breathing 
• neplodnost • težave z dihanjem
In all instances where the use of ETOPOPHOS and associated names is considered for chemotherapy, the physician must evaluate the need and usefulness of the drug against the risk of adverse reactions. 
Zdravnik mora pred uporabo zdravila ETOPOPHOS in povezana imena ovrednotiti potrebo in koristnost zdravljenja glede na tveganje za neželene učinke.
Etoposide phosphate 
Odmerek etopozid fosfata
If ETOPOPHOS and associated names solution contacts the skin or mucosa, immediately wash the skin with soap and water and flush the mucosa with water. 
Če pride zdravilo ETOPOPHOS in povezana imena v stik s kožo ali sluznico, je treba kožo takoj umiti z milom in vodo, sluznico pa izprati z vodo.
The recommended dose of ETOPOPHOS and associated names is 50 to 100 mg/m2/day (etoposide equivalent) on days 1 to 5 or 100 to 120 mg/m2 on days 1, 3, and 5 every 3 to 4 weeks in combination with other drugs indicated in the disease to be treated. 
Priporočeni odmerek zdravila ETOPOPHOS in povezana imena je 50 do 100 mg/m2/dan (ekvivalent etopozida) na 1. do 5. dan ali 100 do 120 mg/m2 na 1., 3. in 5. dan na vsake 3 do 4 tedne v kombinaciji z drugimi zdravili, indiciranimi za zdravljenje bolezni.
Concomitant phenytoin therapy is associated with increased etoposide clearance and reduced efficacy, and other enzyme-inducing antiepileptic therapy may be associated with increased ETOPOPHOS and associated names clearance and reduced efficacy. 
Tudi druga protiepileptična zdravila, ki inducirajo encime, so lahko povezana s povečanim očistkom zdravila ETOPOPHOS in povezana imena in z njegovo zmanjšano učinkovitostjo.
ETOPOPHOS and associated names in paediatric patients has been used in the range of 75 to 150 mg/m2/day (etoposide equivalent) for 2 to 5 days in combination with other antineoplastic agents. 
Zdravilo ETOPOPHOS in povezana imena so pri pediatričnih bolnikih uporabljali v razponu od 75 do 150 mg/m2/dan (ekvivalent etopozida) 2 do 5 dni v kombinaciji z drugimi zdravili z delovanjem na novotvorbe.
How you will be given ETOPOPHOS and associated names 
Kako boste prejeli zdravilo ETOPOPHOS in povezana imena
If etoposide phosphate should contact the skin or mucosa, immediately wash the skin with soap and water and flush the mucosa with water. 
Če pride etopozid fosfat v stik s kožo, sluznico ali očmi, je treba kožo takoj umiti z milom in vodo, sluznico ali oči pa izprati z vodo.
Reinstitution of ETOPOPHOS and associated names therapy should be carried out with caution, and with adequate consideration of the further need for the drug and close attention to possible recurrence of toxicity. 
Ponovno zdravljenje z zdravilom ETOPOPHOS in povezana imena uvedemo previdno in po presoji bolnikove potrebe po nadaljnjem zdravljenju, pri tem pa skrbno pazimo, da se neželeni učinki ne bi ponovili.
Etoposide has been shown to cause metaphase arrest in chick fibroblasts. 
Dokazali so, da etopozid na piščančjih fibroblastih povzroča zaustavljanje delitve v metafazi.
There is the potential for serious adverse reactions in nursing infants from ETOPOPHOS and associated names. 
Obstaja možnost resnih neželenih učinkov, ki jih zdravilo ETOPOPHOS in povezana imena lahko povzroči pri dojenem otroku.
• breathing problems 
• težave s požiranjem
Patients being treated with ETOPOPHOS and associated names must be observed for myelosuppression carefully and frequently both during and after therapy. 
Bolnike je treba skrbno in pogosto spremljati glede znakov mielosupresije med in po zdravljenju z zdravilom ETOPOPHOS in povezana imena.
ETOPOPHOS and associated names should be terminated immediately, followed by the administration of pressor agents, corticosteroids, antihistamines, or volume expanders at the discretion of the physician. 
Zdravljenje z zdravilom ETOPOPHOS in povezana imena je treba takoj ukiniti, po presoji zdravnika pa uporabiti zdravila za zvišanje krvnega tlaka, kortikosteroide, antihistaminike in plazemske ekspanderje.
• bleeding Rare side effects (affecting between 1 in 1,000 and 1 in 10,000 people) 
Redki neželeni učinki (pojavijo se pri manj kot 1 od 1000 bolnikov in več kot 1 od 10.000 bolnikov)
Possible side effects experienced with ETOPOPHOS and associated names that are; 
Možni neželeni učinki, ki so jih opazili pri zdravljenju z zdravilom ETOPOPHOS in povezana imena, ki so
• diarrhoea 
• okužba
ETOPOPHOS and associated names should not be administered to patients with neutrophil counts less than 1,500 cells/mm3 
Zdravila ETOPOPHOS in povezana imena se ne sme dajati bolnikom s številom nevtrofilcev pod 1.500 celic/mm3 ali s številom trombocitov pod 100.000 celic/mm3, razen v primeru, ko je število celic zmanjšano zaradi maligne bolezni.
• 0.9% sodium chloride solution. 
• natrijevega klorida 9 mg/ml (0,9 %) raztopina.
Administration Precautions: As with other potentially toxic compounds, caution should be exercised in handling and preparing the solution of ETOPOPHOS and associated names. 
Previdnostni ukrepi pri dajanju: Pri ravnanju in pripravi raztopine zdravila ETOPOPHOS in povezana imena je potrebna previdnost, tako kot velja za vse potencialno toksične spojine.
After intravenous administration of 14C etoposide (100 to 124 mg/m2), mean recovery of radioactivity in the urine was 
Po intravenski aplikaciji 14Cetopozida (100 do 124 mg/m2) je bila srednja vrednost reaktivnega odmerka v urinu 56 % v 120 urah, v blatu pa 44 % v 120 urah.
The following adverse reactions were reported from ETOPOPHOS and associated names clinical studies and post-marketing experience. 
V kliničnih študijah z zdravilom ETOPOPHOS in povezana imena in v obdobju trženja zdravila so poročali o naslednjih neželenih učinkih.
Fertility 
etopozid
Anaphylactic reactions (see section 4.4), manifested by chills, tachycardia, bronchospasm, dyspnoea, diaphoresis, pyrexia, pruritus, hypertension or hypotension, syncope, nausea, and vomiting have been reported to occur in 3% (7 of 245 patients treated with ETOPOPHOS and associated names in 7 clinical studies) of patients treated with ETOPOPHOS and associated names. 
so poročali pri 3 % (7 od 245 bolnikov, zdravljenih z zdravilom ETOPOPHOS in povezana imena v 7 kliničnih študijah) bolnikov, zdravljenih z zdravilom ETOPOPHOS in povezana imena.
ETOPOPHOS and associated names (see Annex I) 100 mg powder for solution for infusion ETOPOPHOS and associated names (see Annex I) 1000 mg powder for solution for infusion 
ETOPOPHOS in povezana imena (glejte Prilogo I) 100 mg prašek za raztopino za infundiranje ETOPOPHOS in povezana imena (glejte Prilogo I) 1000 mg prašek za raztopino za infundiranje
The resulting stock solution may be administered without further dilution or can be further diluted with 5% glucose solution or 0.9% sodium chloride solution to a final concentration 0.1 mg/ml etoposide. 
Raztopino lahko tudi nadalje razredčite z glukozo 50 mg/ml (5 %) raztopina ali natrijevim kloridom 9 mg/ml (0,9 %) do končne koncentracije 0,1 mg/ml etopozida.
ETOPOPHOS and associated names is indicated in combination with other approved chemotherapeutic agents for the treatment of first line, recurrent or refractory testicular cancer in adults. 
Zdravilo ETOPOPHOS in povezana imena je, v kombinaciji z drugimi odobrenimi kemoterapevtiki, indicirano za prvo linijo zdravljenja rekurentnega ali refraktarnega raka mod pri odraslih.
What ETOPOPHOS and associated names looks like and contents of the pack 
Izgled zdravila ETOPOPHOS in povezana imena in vsebina pakiranja
Acute fatal reactions associated with bronchospasm have also been reported with etoposide phosphate. 
Pri zdravljenju z etopozid fosfatom so poročali tudi o akutnih reakcijah z bronhospazmom, ki so se končale s smrtjo.
Each vial contains 1136 mg etoposide phosphate equivalent to 1000 mg etoposide. 
Ena viala vsebuje 1000 mg etopozida v obliki 1136 mg etopozid fosfata.
Anaphylactic reactions have been reported to occur during or immediately after intravenous administration of etoposide phosphate. 
Med intravenskim dajanjem etopozid fosfata ali takoj po njem so bile opisane reakcije anafilaktičnega tipa.
6.6 Special precautions for disposal and other handling Procedures for proper handling and disposal of anti-cancer drugs should be followed. 
6.6 Posebni varnostni ukrepi za odstranjevanje <in ravnanje z zdravilom
• 5% glucose solution or 
• glukoze 50 mg/ml (5 %) raztopina ali
infections, or at a thrombocyte count below 25,000 cells/mm3, which is not caused by the disease. 
Poleg tega je treba odmerek prilagoditi, če se pojavijo zvišana telesna temperatura, okužbe ali če je število trombocitov nižje od 25.000 celic/mm3 razen v primeru, ko je število celic zmanjšano zaradi same bolezni.
ETOPOPHOS and associated names is indicated in combination with other approved chemotherapeutic agents for the treatment of small-cell lung cancer in adults. 
Zdravilo ETOPOPHOS in povezana imena je, v kombinaciji z drugimi odobrenimi kemoterapevtiki, indicirano za zdravljenje drobnoceličnega pljučnega raka pri odraslih.
See Annex I - To be completed nationally 
Glejte Prilogo I - izpolni država članica.
The recommended dose of ETOPOPHOS and associated names in adult patients is 50 to 100 mg/m2/day (etoposide equivalent) on days 1 to 5 or 100 to 120 mg/m2 on days 1, 3, and 5 every 3 to 4 
Priporočeni odmerek zdravila ETOPOPHOS in povezana imena pri odraslih bolnikih je 50 do 100 mg/m2/dan (ekvivalent etopozida), 1. do 5. dan ali 100 do 120 mg/m2, 1., 3. in 5. dan na vsake 3 do 4 tedne v kombinaciji z drugimi zdravili, odobreni za uporabo pri zdravljeni bolezni.
You must not breastfeed while you are receiving ETOPOPHOS and associated names. 
Med jemanjem zdravila ETOPOPHOS in povezana imena ne smete dojiti.
ETOPOPHOS and associated names is used in the treatment of certain types of cancers in adults: 
Zdravilo ETOPOPHOS in povezana imena uporabljamo za zdravljenje določenih vrst raka pri odraslih: - rak mod
After reconstitution, the solution can be administered without further dilution or it can be further diluted with 5% glucose solution or 0.9% sodium chloride solution to obtain concentrations as low as 0.1 mg/ml etoposide. 
Raztopino lahko tudi nadalje razredčite z glukozo 50 mg/ml (5 %) raztopina ali natrijevim kloridom 9 mg/ml (0,9 %), da boste dobili nizke koncentracije 0,1 mg/ml etopozida.